{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:01:37Z","timestamp":1783418497650,"version":"3.54.6"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451\u201003\u20109\/2021\u201014\/200161"],"award-info":[{"award-number":["451\u201003\u20109\/2021\u201014\/200161"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this study was to analyse potential drug\u2013drug interactions (pDDIs) and their potential adverse drug reactions (ADRs) among hypertensive patients. Moreover, we investigated the possibility of reducing pDDIs with different treatment choices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a cross\u2010sectional study including all outpatients with hypertension and two or more medications, treated in a university hospital in Serbia. Lexicomp Interact (Lexi\u2010Comp, Inc., Hudson, OH) was used for identification of pDDIs and potential ADRs. Treatment choices were explored according to patient characteristics, treatment guidelines and the interacting potential of drugs. Data were analysed using descriptive analysis and multiple logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 350 patients were included in this study, with average age (77 [36\u201398] years and 6.1 [2.5]) medications. The majority of patients (86.0%) had at least one clinically significant pDDI, and the average was 3.78 (3.90) (range 1\u201325). Suggestions for treatment change aimed mainly at eliminating drug duplications, reducing the use of thiazide diuretics, sulfonylureas, alpha\u2010lipoic acid and pentoxifylline and increasing the use of calcium\u2010channel blockers, when appropriate. pDDIs would have decreased to 2.10 (2.52), <jats:italic>P<\/jats:italic>\u2009&lt;.001, yet male gender, \u22656 medications, cardiovascular diseases, diabetes, benign prostatic hyperplasia, would be predictive of two or more pDDIs. The main potential adverse outcomes of pDDIs were hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Careful choice of drugs can reduce but not eliminate pDDIs and their potential ADRs in hypertensive patients. Close monitoring for hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis is necessary.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15168","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T02:34:16Z","timestamp":1638585256000},"page":"2340-2348","source":"Crossref","is-referenced-by-count":8,"title":["The impact of treatment choices on potential drug\u2013drug interactions in hypertensive patients"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-7584","authenticated-orcid":false,"given":"Aneta","family":"Peri\u0107","sequence":"first","affiliation":[{"name":"Sector for Pharmacy Military Medical Academy  Belgrade Serbia"},{"name":"Faculty of Medicine of the Military Medical Academy University of Defence  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-4628","authenticated-orcid":false,"given":"Ana","family":"Udilovi\u0107","sequence":"additional","affiliation":[{"name":"Deutsche Rentenversicherung Bayern S\u00fcd Rehafachzentrum Bad F\u00fcssing\u2010Passau Standort Passau  Pasau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-8525","authenticated-orcid":false,"given":"Silva","family":"Dobri\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of the Military Medical Academy University of Defence  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5791-2145","authenticated-orcid":false,"given":"Sandra","family":"Vezmar Kova\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy University of Belgrade  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20110077"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31145-6"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00049"},{"issue":"11","key":"e_1_2_11_5_1","article-title":"Potential drug\u2013drug interactions among medications prescribed to hypertensive patients","volume":"8","author":"Kothari N","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S2468"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2288-1"},{"key":"e_1_2_11_9_1","first-page":"w13043","article-title":"Assessment of potential drug\u2013drug interactions at hospital discharge","volume":"140","author":"Bertoli R","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1177-8"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12754"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1668-z"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1745-3"},{"key":"e_1_2_11_14_1","volume-title":"ICD\u201010: International statistical classification of diseases and related health problems: tenth revision","author":"World Health Organization","year":"2010"},{"key":"e_1_2_11_15_1","volume-title":"Guidelines for ATC classification and DDD assignment 2020","year":"2018"},{"key":"e_1_2_11_16_1","volume-title":"Lexi\u2010Interact","author":"Lexi\u2010Comp Online","year":"2019"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90144-C"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-010-9442-5"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13005"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1531-7"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-021-02183-0"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55070332"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020239"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2019.11.009"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1509-89"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijpp.12167"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.2143\/ACB.68.1.2062714"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03107-y"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1647021"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.18433\/J3CC86"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1197\/jamia.M2313"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00951-y"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1287"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht246"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd11.130389"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1078-7"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-05131-7"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2357-5"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03500.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15168","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T22:28:41Z","timestamp":1693002521000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/bcp.15168"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15168","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,18]]}}}